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Summary
Background.— Heart failure with systolic dysfunction occurs frequently. Studies in North Amer-syndromes;Prevalence;
Congestive heart
failure
ica and Germany have shown a high prevalence of sleep-disordered breathing in patients with
heart failure.
Aims.— To assess the prevalence of sleep-disordered breathing and its associated risk factors
in French patients with heart failure.
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MOTS CLÉS
Syndrome d’apnées
du sommeil ;
Risque facteur ;
Insufﬁsance
cardiaque
d’apnées du sommeil à une prévalence élevée avec une majorité de forme obstructive. Le
syndrome d’apnées du sommeil est moins fréquent et moins sévère chez la femme. Ces résultats
soulèvent la question la nécessité d’un dépistage systématique des syndromes d’apnées du
ion.
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bbreviations
HF congestive heart failure
SA central sleep apnoea
VEF left ventricular ejection fraction
YHA New York Heart Association
SA obstructive sleep apnoea
DB sleep-disordered breathing
ackground
HF is a leading cause of morbidity and mortality world-
ide. Studies in North America [1] and Germany [2] found
hat SDB was present in as many as 51—76% of patients with
HF, and it has been shown to be associated with ventricular
ysfunction and increased mortality in this setting [3,4].
ome studies have suggested that nocturnal ventilation
C
c
H
2s droits réservés.
ay reduce mortality and morbidity in CHF patients with
DB [5,6]. The prevalence of SDB in a large French CHF
opulation has not been assessed recently, although some
ata have been published on small groups of patients
7,8] and in other countries [1,2,9—15]. Accordingly, our
tudy aimed to determine the prevalence and character-
stics of SDB in a French cohort of patients with stable
HF.
ethods
tudy designA. Paulino et al.
Methods.— A total of 316 patients with stable heart failure and a left ventricular ejection
fraction less or equal to 45% underwent polygraphy prospectively to diagnose sleep apnoea
syndrome, deﬁned as an apnoea-hypopnoea index greater or equal to 10 events/h.
Results.— Mean age, left ventricular ejection fraction, and body mass index were 59± 13 years,
30± 11% and 28± 6 kg/m2, respectively. The prevalence of sleep breathing disorder was 81%
(n = 256); 30% of syndromes were classiﬁed as central and 70% as obstructive. The mean apnoea-
hypopnoea index was high (30± 3 events/h) and a large proportion (41%) of syndromes had an
apnoea-hypopnoea index greater or equal to 30 events/h. A central sleep apnoea syndrome
pattern was associated with more severe heart failure and a more elevated apnoea-hypopnoea
index than an obstructive pattern. The prevalence of sleep-disordered breathing was lower in
women than in men (64% versus 85%; 2 = 0.0003) as was its severity (mean apnoea-hypopnoea
index 15± 13 events/h versus 27± 19 events/h, p = 0.0001).
Conclusion.— The prevalence of sleep-disordered breathing was high in a French heart failure
population, with most syndromes having an obstructive pattern. Prevalence and severity were
higher in men than in women.
© 2009 Elsevier Masson SAS. All rights reserved.
Résumé
Contexte.— Des études nord américaines et allemande ont démontré une prévalence impor-
tante des syndromes d’apnées du sommeil dans l’insufﬁsance cardiaque. Notre objectif a été
de déﬁnir la prévalence et les facteurs de risque de ces syndromes dans une cohorte franc¸aise
de patient en insufﬁsance cardiaque.
Méthodes.— Trois cent seize patients avec une insufﬁsance cardiaque déﬁnie par une fraction
d’éjection ventriculaire gauche inférieure ou égale à 45% ont été dépistés pour le syndrome
d’apnées du sommeil par une polygraphie (indice apnée-hypopnée≥ 10 par heures).
Résultats.— L’âge moyen, la fraction d’éjection ventriculaire gauche, l’index de masse cor-
porelle étaient respectivement 59± 13 années, 30± 11% et 28± 6 kg/m. La prévalence du
syndrome d’apnées du sommeil était de 81% avec un indice apnée-hypopnée moyen de 30± 3
par heures dans ce groupe. Le pourcentage des syndromes d’apnées du sommeil sévères (indice
apnée-hypopnée supérieure ou égale à 30 par heures) était de 41%. Ces syndromes d’apnées du
sommeil étaient de type central dans 30 % des cas et dans 70 % obstructifs. Les patients avec un
type central étaient plus sévères que les obstructifs (indice apnée-hypopnée = 39± 17 par heures
versus 26± 16 par heures, p < 0,0001). La prévalence et la sévérité du syndrome d’apnées du
sommeil étaient moins importantes chez les femmes (respectivement : 2 = 0,0003 ; p = 0,0001).
Conclusion.— Dans une population franc¸aise de patients insufﬁsants cardiaques, le syndromeonsecutive patients with stable CHF admitted to the
ardiology ward of Henri Mondor University Teaching
ospital for a systematic check-up between 2001 and
007 were included in the study based on the following
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based on the 10 events/h cut-off level. The mean apnoea-
hypopnoea index was high (30± 18 events/h) in the SDB
group. Accordingly, the prevalence of severe SDB (apnoea-
hypopnoea index greater or equal to 30 events/h) was highPrevalence of sleep-disordered breathing in a French heart
inclusion criteria: LVEF greater or equal to 45%, stable
optimized heart failure therapy and no episode of acute
heart failure within the past 4weeks. Exclusion criteria
were the presence of clinical signs of decompensated heart
failure, severe chronic obstructive pulmonary disease and
known SDB. The study complied with the Declaration of
Helsinki and was approved by the local ethics committee.
Informed consent was obtained from each patient.
Patient assessment
Clinical and demographic patient characteristics were
recorded (age, sex and body mass index). NYHA class
was determined and the main cause of CHF was speci-
ﬁed (ischaemic or not). The standard CHF therapy was
noted for each patient (angiotensin-converting enzyme
inhibitors, angiotensin II receptor blockers, beta-blockers,
aldosterone antagonists or diuretics) and whether an
implantable cardioverter-deﬁbrillator and/or a biventric-
ular assist device had been inserted. A standard 12-lead
electrocardiogram was obtained to determine whether the
patient was in sinus rhythm or atrial ﬁbrillation.
Polygraphy recording and analysis
The polygraph was recorded overnight in the cardiol-
ogy ward using a computerized data acquisition system
(EmblettaTM, ResMed, Saint-Priest, France), which recorded
oronasal airﬂow from nasal pressure and mouth ther-
mistance, chest and abdominal effort by inductance
plethysmography, pulse oximetry, snoring, actimetry and
body position. Regarding trace quality, we took into account
only recordings of greater or equal to 4 h duration without
any trace missing. A questionnaire related to sleep qual-
ity and estimated sleep duration during the night of the
recording and the Epworth sleepiness scale was also com-
pleted.
According to international recommendations [16],
apnoea was deﬁned as a decrease superior to 80% in nasal-
airﬂow lasting greater than 10 s and hypopnoea was deﬁned
as a decrease of greater or equal to 30% in nasal-airﬂow
with greater or equal to 4% desaturation. The number of
apnoea-hypopnoea events per hour (apnoea-hypopnoea
index) was determined after the exclusion of periods with
movements, which were considered to be wake periods. A
diagnosis of SDB was considered if the apnoea-hypopnoea
index was greater or equal to 10 events/h.
Apnoea without chest or abdominal movements, with or
without Cheyne-Stokes respiration, was classiﬁed as CSA and
apnoea with chest and abdominal movements was classiﬁed
as OSA. As published previously [17], hypopnoeas were con-
sidered to be obstructive when there was evidence of upper
airway obstruction, such as snoring, paradoxical respiratory
band movement or inspiratory ﬂow limitation through the
nasal cannula; central hypopnoea, in contrast, was associ-
ated with in-phase respiratory movements and no evidence
of inspiratory ﬂow limitation. SDB was considered to be cen-
tral if greater than 50% of apnoea/hypopnoea events were
central and obstructive if greater than 50% were obstruc-
tive. All recordings were scored manually by two scorers (MS
and M-P d’O) who were blinded to the cardiac assessment.
If the scorers disagreed about the SDB type (central versus
F
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bstructive), the polygraph trace was reread by both scorers
ogether to reach an agreement.
tatistical analysis
ata were expressed as means± standard deviations (S.D.),
nless speciﬁed otherwise. Data distributed abnormally (B-
ype natriuretic peptide concentration, apnoea-hypopnoea
ndex, apnoea index, hypopnoea index, time with saturation
ess than 90%) were transformed logarithmically to achieve
normal distribution. An unpaired t test was used to assess
he differences between two groups and a two-way analy-
is 2 test was used to compare proportions. A p-value less
han 0.05 was considered to be statistically signiﬁcant. A
onferroni correction was applied for multiple comparisons;
p-value less than 0.0167 was then considered to be signif-
cant. Statistical analyses were done using View Statistical
nalytical System (SAS, Cary, NC, USA).
esults
omparison of patients with and without SDB
total of 316 patients with CHF were included. Most (83%)
atients were men and 49% had an ischaemic cardiopathy.
ean NYHA class and LVEF were 2.5± 0.8 and 30± 11%,
espectively. Prevalence of SDB was high overall: 256 (81.2%)
atients had SDB deﬁned by an apnoea-hypopnoea index
reater or equal to 10 events/h, and nearly 90% of patients
ad SDB deﬁned by an apnoea-hypopnoea index greater or
qual to 5 events/h, as recommended [16]. Further compar-
sons of patients with SDB and without SDB (non-SDB) wereigure 1. Prevalence of non-SDB, CSA and OSA, using various
pnoea-hypopnoea index cut-off levels (5 events/h, 10 events/h,
0 events/h and 30 events/h).
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Table 1 Baseline patient characteristics.
Characteristics All patients(n = 316) SDB(n = 256) Non-SDB(n = 60) CSA (n = 78) OSA(n = 178)
Age (years) 59± 3 60± 13a 55± 14 60± 13 60± 12c
Men, n (%) 261 (83) 221 (86)a 40 (67) 70 (90) 151 (85)
Body mass index (kg/m2) 28± 6 28± 5a 25.6± 4.4 27.9± 5.1c 28.3± 5.4c
NYHA class 2.5± 0.8 2.4± 0.7 2.3± 0.8 2.6± 0.8c 2.4± 0.7
LVEF (%) 30± 11 30± 10 31± 11 26± 8c,d 31± 10
B-type natriuretic peptide
(pg/mL)
520± 654 547± 684a 406± 501 681± 781c,d 501± 644
Ischaemic, n (%) 156 (49) 133 (52) 23 (38) 39 (50) 94 (53)
Atrial ﬁbrillation, n (%) 66 (21) 59 (23) 7 (12)b 23 (29) 36 (20)
Beta-blocker (%) 82 84a 73b 75 88
Angiotensin-converting
enzyme inhibitor (%)
80 79 83 85 76
Angiotensin II receptor
blocker (%)
18 19 14 11 22
Spironolactone (%) 58 57 64 70 53
Diuretic (%) 78 82a 64b 92 79
Cardiac resynchronization, n
(%)
37 (12) 28 (11) 9 (15) 10 (13) 18 (10)
a p < 0.05 versus non-SDB.
b 2 < 0.05 for OSA, CSA, and non-SDB distribution comparison (%).
c p < 0.0167 versus non-SDB.
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41% of SDB patients and 33% of the cohort; Fig. 1). SDB
atients were more frequently men, older, with a higher
revalence of atrial ﬁbrillation and a higher B-type natri-
retic peptide concentration and body mass index compared
ith non-SDB patients. LVEF and NYHA class were similar in
DB and non-SDB patients. All patients were receiving stan-
ard CHF therapy, but a higher proportion of SDB patients
ere receiving beta-blockers and diuretics.
omparison of patients with OSA, with CSR
nd without SDBf the total population, 56% were classiﬁed as having OSA
nd 25% as having CSA (Table 1). CSA patients had more
evere CHF, with a signiﬁcantly lower LVEF and higher B-
ype natriuretic peptide concentration than OSA patients
nd non-SDB patients. CSA patients also had a more severe
C
M
w
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Table 2 Polygraphic characteristics.
Non-S
Epworth score 8 ±
Apnoea-hypopnoea index (events/h) 4 ±
Apnoea index (events/h) 1 ±
Hypopnoea index (events/h) 4 ±
Oxygen desaturation index (events/h) 4.4 ±
Lowest oxygen saturation (%) 86 ±
Time in bed with oxygen saturation < 90% (%) 22 ±
a p < 0.0167 versus non-SDB.
b p < 0.0167 versus OSA using Bonferroni correction.leep apnoea syndrome than OSA patients, with a signiﬁ-
antly higher apnoea-hypopnoea index, apnoea index and
xygen desaturation index (Table 2). CSA patients were
ore often men and more frequently had atrial ﬁbrilla-
ion. After adjustment for multiple comparisons between
he OSA, CSA and non-SDB groups, both OSA and CSA patients
ad a higher body mass index than non-SDB patients, but
nly CSA patients had atrial ﬁbrillation more frequently than
on-SDB patients. CSA patients received beta-blockers less
requently (because of intolerance) and diuretics more fre-
uently than OSA patients.omparison between sexes
ost patients were men (Tables 1 and 3). Compared with
omen, men were more often smokers and presented
ore frequently with ischaemic cardiopathy, whereas body
DB(n = 60) CSA(n = 78) OSA(n = 178)
5 7 ± 5 7 ± 5
3 39 ± 17a,b 26 ± 16a
1 20 ± 15a,b 10 ± 14a
3 21 ± 33a 16 ± 9a
5 29 ± 20a,b 17 ± 16a
20 74 ± 18a,b 81 ± 9
55 59 ± 87a 42 ± 72
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index class (non-SDB, 10—19 events/h (inclusive), 20—29 events/h
(inclusive) and greater or equal to 30 events/h.
mass index, age and presence of hypertension were simi-
lar between the sexes (Table 3). Severity of CHF and type
of medical treatment were also similar between the sexes,
with regard to the entire population and the SDB group
(NYHA class, LVEF and B-type natriuretic peptide concentra-
tion were not statistically different; Table 3). Women had
less frequent and less severe SDB (Tables 1 and 4; Fig. 2)
in terms of both apnoea-hypopnoea index (18± 9 events/h
versus 27± 17 events/h in men, p = 0.008) and apnoea index
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Table 3 Sex-speciﬁc patient characteristics.
Men(
Age (years) 60±
Weight (kg) 83±
Height (cm) 173±
Body mass index (kg/m2) 28±
Diabetes (%) 20
Cholesterol (%) 54
Hypertension (%) 47
Smoker (%) 72
Ischaemic cardiopathy (%) 54
NYHA class 2.4±
LVEF (%) 30±
B-type natriuretic peptide (pg/mL) 524±
Atrial ﬁbrillation, n (%) 13
Beta-blocker (%) 82
Angiotensin-converting enzyme inhibitor (%) 80
Angiotensin II receptor blocker (%) 16
Spironolactone (%) 56
Diuretic (%) 79
Multisite ventricular pacing, n (%) 12re cohort 173
5± 5 events/h versus 11± 15 events/h in men, p = 0.03). In
he SBD group, the respective proportions of patients with
SA and OSA were similar between the sexes (2 = 0.29).
iscussion
o our knowledge, this study is the ﬁrst large-scale prospec-
ive French study investigating the prevalence of SDB in
atients with stable CHF. The major ﬁndings of the study
ere that the prevalence of SDB was high (81%) in CHF
atients, the prevalence of severe SDB (apnoea-hypopnoea
ndex greater or equal to 30 events/h) was also high (41%
f patients with SDB) and that women with CHF have less
requent and less severe SDB than men with CHF.
The prevalence of SDB in CHF patients is known to
e higher than in general population. In the latter, the
revalence varies between 2% and 4% in women and men,
espectively, if daytime sleepiness is taken into account
o deﬁne the sleep apnoea syndrome, but the prevalence
ncreases to 9% and 24%, respectively, if only SDB is con-
idered, irrespective of associated daytime sleepiness [18].
everal factors contribute to the higher prevalence in CHF,
ncluding older age, the association of established risk fac-
ors such as obesity and smoking habits, and the cardiac
athology itself, which predisposes to CSA. The prevalence
n our study is higher than that in most studies published
ecently [2,9—12], which reported prevalences ranging from
1 [10] to 75% [2] for similar apnoea-hypopnoea index cut-off
evels. Selection bias is always a possibility in a single-centre
tudy. In this respect, trace quality and event scoring are key
ssues. Scoring was done by two different scorers accord-
ng to international recommendations and in line with other
tudies [12]. In cases of discrepancy between scorers, the
race was reread to reach agreement. The higher preva-
ence in our study may also be a French particularity, as
n = 261) Women(n = 55) p-value
13 57± 15 0.20
17 72± 15 < 0.0001
8 163± 7 < 0.0001
6 27± 32 0.41
34 0.046
45 0.25
53 0.48
29 < 0.0001
29 < 0.001
0.7 2.5± 0.8 0.61
10 30± 10 0.67
691 503± 488 0.88
23 0.10
83 0.80
74 0.24
28 0.037
71 0.016
75 0.57
9 0.85
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Table 4 Sex-speciﬁc polygraphic characteristics.
Men(n = 261) Women(n = 55) p-value
Prevalence of SDB (%) 85 64 < 0.001
Prevalence of CSA (%) 27 15 < 0.001
Prevalence of OSA (%) 58 49 0.002
Epworth score 7± 5 8± 4 0.56
Apnoea-hypopnoea index (events/h) 30± 19 15± 14 < 0.001
Apnoea index (events/h) 11± 15 6± 9 0.008
Hypopnoea index (events/h) 16± 20 10± 9 0.020
Oxygen desaturation index (events/h) 19± 18 10± 10 < 0.001
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similar prevalence was found by Tremel et al., although in
smaller group [7]. However, this hypothesis may be con-
ounded by the similarities between our study and other
tudies in terms of patient characteristics (demographic,
nthropometric treatment and CHF aetiology), CHF severity
nd the screening of consecutive patients irrespective of SDB
ymptoms, using similar polygraphic ambulatory monitors.
We observed a predominance of OSA over CSA. This result
ontrasts with previous data that showed similar proportions
f both categories of SDB [2,11,15] or a clear predominance
f CSA over OSA [9,12,14], but is in line with the recent
tudy by Schulz et al. [10]. In both our study and the study by
chulz et al., most (∼90%) patients received beta-blockers.
his may have contributed to a decrease in CSA prevalence,
s two recent studies have shown that beta-blockers can
mprove cardiac function and decrease CSA [19,20]. Another
otential contributory factor was our inclusion of patients
ith biventricular pacing, which is also known to reduce
SA [2]. Lastly, a higher body mass index in our cohort com-
ared with others [2] may have contributed to an increase
n OSA prevalence. In our study, CSA was associated with
en and atrial ﬁbrillation, in line with previous publica-
ions, but not with age, in contrast with the study by Sin
t al. [15] but in line with the study by Javaheri et al.
1].
We included both men and women in our study, allow-
ng a comparison between the sexes. In accordance with
HF epidemiological characteristics, women represented
nly 15% of our population [21]. Two important ﬁndings of
ur study were that both CSA and OSA occurred less fre-
uently in women than in men and that SDB was less severe
n women in terms of apnoea-hypopnoea index, despite
imilar degrees of heart dysfunction (as indicated by LVEF,
YHA class, and B-type natriuretic peptide concentration).
everal different mechanisms may account for these differ-
nces. Firstly, differences in sleep characteristics between
he sexes have been described, with men having a greater
umber of sleep-wake transitions and shorter slow wave
leep; both these factors contribute to unstable sleep, which
redisposes to central apnoea [22]. Secondly, studies have
hown that progesterone has a positive impact on geniglos-
us muscle activity, increasing airway luminal calibre and
aking upper airway closure less frequent during sleep
23,24]. Accordingly, an increase in SDB prevalence has been
hown in post-menopausal women in the general population
25].
o
r
n
a
h19 83± 24 0.24
79 21± 40 0.020
imitations
hey are several limitations to our study. With regard to OSA
ex differences, we did not measure neck circumference; an
ncrease in this variable is an established risk factor for OSA.
here were also some methodological issues. Firstly, and
n contrast with earlier studies [15], SDB was diagnosed by
olygraphy and not by attended polysomnography. The lack
f electroencephalographic channels could have led to an
nderestimation of SDB severity, as the apnoea-hypopnoea
ndex is calculated using recording duration rather than total
leep time. This factor may be crucial, as CHF patients are
nown to have poor sleep quality, with sleep fragmentation
nd an increase in waking after sleep onset, either secondary
o SDB or to periodic limb movements, or due to the CHF
tself [14]. However, exclusion of movement periods mea-
ured by actimetry included in the polygraph overcomes this
ias partially. Underestimation of the apnoea-hypopnoea
ndex may also come from hypopnoea that is associated with
ortical arousals rather than with oxygen desaturation. In
he latest American Sleep Disorder Association recommen-
ations [16], measurement of arousal does not appear in
he deﬁnition of hypopnoea in a routine setting. In addition,
owever, cortical arousals are associated with autonomic
rousals, which are visible as heart rate increases, and
ith pulse plethysmography modiﬁcations; both of these
ignals are available on the cardio-respiratory polygraph.
nother issue is the distinction between obstructive and
entral events. The gold standard is the measurement of
esophageal pressure that shows an increase in respiratory
ffort in the case of an obstructive event and a decrease
n effort in central hypopnoea. However, this is not feasible
n the context of a study such as ours (i.e. a prospective
tudy of consecutive patients in a cardiology ward) and is
ven contraindicated in the case of CHF patients treated
requently with anticoagulants or antiaggregants. In addi-
ion, the measurement of respiratory effort by inductance
lethysmography appears in more recent recommendations
16]. Also, in our study, all cardiorespiratory polygraph
races were scored by two independent physicians. In the
ase of disagreement over the SDB type (central versus
bstructive), the two scorers reread the trace together to
each an agreement. This method has caveats, as it does
ot avoid a centre effect, but it overcomes interscorer vari-
bility. Of note, variation in type and severity of SDB in CHF
as been studied systematically recently [17], raising the
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question of whether conventional continuous positive airway
pressure or servo-adaptive ventilation is the best treatment
[6]. The latter has the advantage in the successful treatment
of both central and obstructive components of SDB [26].
Conclusion
In summary, our study showed a high prevalence of SDB
in a large prospective French cohort of CHF patients, and
differences between the sexes. The results suggest that sys-
tematic SDB screening is needed in the CHF population.
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